1. Scrip
  2. >>Business
  3. >>Deals
  4. >>Deal Watch

Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab

 
• By Dexter Jie Yan, Lisa Takagi, Jung Won Shin, Anju Ghangurde, Joseph Haas, and Ian Haydock

Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.

Asia Deal Watch
• Source: Alamy

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.

Shanghai Junshi Biosciences Co., Ltd. and Rxilient Biotech Pte. Ltd. unveiled a collaboration on 28 March to develop...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal Watch

Deal Watch: AstraZeneca Remains Busy In AI, Via Deals With Immunai, Turbine And Algen

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.

Asia Deal Watch: Chugai Teams With Rani On Oral Version Of Rare Disease Antibody Drug

 
• By Joseph Haas, Jung Won Shin, Lisa Takagi, Xu Hu, and Vibha Ravi

Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.

Deal Watch: Clywedog, Barinthus To Merge With Focus On Diabetes, Celiac Disease

 
• By Joseph Haas

Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.

Asia Deal Watch: Kyorin Collaborates On Hinge’s Multispecific Antibody For Lupus

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Elix/Tohoku U., Hanmi/Gilead/Hope Health, Heartseed/Novo Nordisk, Novatim/VRise, Qurient/Synaffix, Huons/Therapex, Mochida/Itochu/AND Pharma, Sovargen/Angelini, Starpharma/Genentech, Axcelead/xFOREST and Daiichi Sankyo/Immuto.

More from Deals

Who Needs Metsera More? Pfizer Ups Ante Vs. Novo With Lawsuit

 
• By Andrew McConaghie

Both companies are in need of a major strategic win but Novo has signalled willingness to take a bigger risk on Metsera.

Pfizer Brands Novo’s Metsera Bid Anti-Competitive, Vows Legal Fight

 
• By Andrew McConaghie

The US pharma company has come out all guns blazing, claiming that Novo Nordisk is looking to block new competitors entering the anti-obesity market.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.